Sciety leads SEK 87 million financing round in Neogap Therapeutics

Sciety led a SEK 87 million financing round in Neogap Therapeutics to advance pTTL, a personalised T‑cell immunotherapy currently in a Phase I/II colorectal cancer trial, and to build the clinical data required for the next development stage. Neogap has treated initial patients and reported positive early safety data, received Swedish regulator approval to administer full doses across the trial, and established a manufacturing framework with CDMO NorthX Biologics; the company estimates pTTL potential annual revenue of roughly USD 1.4–1.9 billion versus a ~USD 9 billion 7MM colorectal market in 2024. The funding and Sciety’s continued capital support de‑risk near‑term execution on clinical and manufacturing milestones that underpin future value inflection points.

Analysis

Market structure: Neogap’s SEK 87m round signals continued capital flow into personalised autologous T‑cell therapies and will directly benefit CDMOs (e.g., Lonza LZAGY, Catalent CTLT) and AI/neoantigen platforms (BioNTech BNTX, Moderna MRNA). If pTTL captures even 15–20% of the USD9bn colorectal market (as company projects USD1.4–1.9bn), incumbents selling standard chemo/mono‑antibody regimens will face meaningful share loss and pricing pressure for advanced CRC over 3–5 years. Manufacturing capacity remains the supply choke-point, implying rising utilization and pricing power for GMP cell‑therapy CDMOs over the next 12–36 months.

Risk assessment: Key tail risks are binary clinical failure (safety/efficacy) or inability to scale autologous manufacturing — assign current probability of late‑stage commercial success at 10–30% for CRC cell therapies. Immediate market impact is negligible (days), short term (3–12 months) is trial readouts and dose expansions that reprice equity, long term (24–60 months) is regulatory approval, reimbursement and commercialization. Hidden dependency: pTTL’s value proposition hinges on AI neoantigen selection accuracy and CDMO reproducibility; payer acceptance is uncertain given potential >$100k treatment cost per patient.

Trade implications: Tactical allocations: establish small, asymmetrical exposure to leaders of neoantigen/cell therapy ecosystems — 1–2% NAV in BNTX (buy 12–18 month LEAPS calls) and 1% NAV in GILD (equity or 12‑month call) to capture M&A/partnering upside. Pair trade: long CDMO exposure (CTLT 1% NAV or LZAGY 1%) vs short XBI (size equal notional) to play capacity scarcity and wider biotech dispersion over 6–18 months. Use concentrated call spreads (buy LEAPS call / sell nearer expiry call) to limit premium and target 30–100% upside.

Contrarian view: The market is underpricing manufacturing and payer risk — valuation assumptions that yield USD1.4–1.9bn revenue require >20k treated patients/year at >$70k/treatment or much higher per‑patient pricing; this is optimistic absent demonstrated durable responses. Historical parallel: early CAR‑T enthusiasm produced dramatic M&A followed by pricing pressure and narrower use; similar mean reversion could punish pure‑play small biotechs. Action should be small, catalyst‑driven, and contingent on Phase I/II efficacy signals within 3–12 months.

Key Decisions for Investors

• Establish a 1.5% NAV long exposure to BioNTech (BNTX) via 12–18 month LEAPS calls to capture neoantigen/IP and vaccine platform upside; size allows doubling on a >50% positive efficacy signal in 3–12 months.
• Allocate 1% NAV to Gilead Sciences (GILD) equity or 12‑month calls to gain cell‑therapy platform and M&A optionality; trim if GILD rallies >15% within 90 days.
• Implement a relative‑value pair: long 1% NAV in Catalent (CTLT) or Lonza (LZAGY OTC) vs short equal‑notional XBI (ETF) to express CDMO scarcity and hedge broad biotech downside; target 6–18 month horizon, take profits if spread widens >15%.
• Use defined‑risk options: buy call spreads (debit) rather than naked calls on BNTX/MRNA to cap downside — e.g., buy 12‑18 month call and sell a nearer strike to limit cost to ≤0.7% NAV per position.
• Do NOT direct co‑invest in similar early autologous players >3% NAV without completion of meaningful efficacy readouts; wait for objective response rate or dose‑expansion data in the next 3–12 months before scaling private/venture exposure.